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body, molecules derived from microbial 
pathogens and/or the host, recruit PMNs 
via chemotactic mechanisms from the 
blood stream to sites of infection. PMNs 
evade from the blood vessels into the tissue 
to ingest the pathogenic microorganisms 
by phagocytosis and to eliminate bacteria 
and fungi via their arsenal of cytotoxic sub-
stances. However, besides the beneficial 
role of PMN activity with infections, hyper-
activity of PMNs can be detrimental for 
patients, if PMNs are excessively recruited 
into injured tissues.[1] Such conditions 
are, for example, reported for multiple 
injured patients suffering from blunt thorax 
trauma, where the enhanced chemotactic 
recruitment of PMNs and monocytic cells 
into the lungs and the subsequent release 
of their toxic mediators enhance the alveolar 
barrier breakdown resulting in local and 
systemic inflammation and contributing to 
the poor outcome of such patients.[1–6]
Therefore, the targeted, cell type-selec-
tive, pharmaco logical inhibition of exces-
sive chemotactic recruitment of PMNs 
will enhance our understanding of their role in the first-line 
defense against microbes and their contribution to the exces-
sive inflammatory responses after traumatic tissue injury. Since 
migration, chemotaxis, and phagocytosis of PMNs depend on 
the remodeling of the actin cytoskeleton, which is regulated by 
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1. Introduction
Polymorphonuclear leukocytes, also termed PMNs or neutro-
phils, are the most abundant leukocytes in human blood and a 
major component of the innate immune system. In the human 
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Rho-GTPases,[7–12] PMN-selective Rho inhibition represents an 
attractive strategy to downmodulate excessive PMN recruitment 
from blood into tissues after traumatic injury.[13] Moreover, 
PMN-selective molecules modulating Rho-signaling and actin 
dynamics of these immune cells certainly offer great potential 
as molecular tools in cell biology and experimental pharma-
cology to decipher the role of PMN activity in both infection 
and inflammation. In this context, the C3 enzymes from 
Clostridium (C.) botulinum (C3bot1) and C. limosum (C3lim) are 
of major interest as they represent the only known specific Rho 
inhibitors.[6,10,14–16] C3 proteins are taken up into the cytosol 
of monocytic cells where they catalyze the specific mono-
ribosylation of Rho A and Rho B. This inhibits Rho-signaling 
resulting in the reorganization of actin filaments accompanied 
by a characteristic change in cell morphology.[11,17–21] Recently, 
it has been demonstrated by our groups that the targeted phar-
macological inhibition of Rho activity by C3 enzyme inhibits 
the migration and chemotaxis of primary human monocytes 
ex vivo.[11] Moreover, the local intra-tracheal application of this 
Rho-inhibitor prevented the excessive recruitment of mono-
cytic cells from the blood into the lungs of mice after blunt 
thorax trauma.[11] However, the C3 Rho-inhibitor has no effect 
on PMNs ex vivo and does not reduce the amount of PMNs in 
the lungs of mice after blunt thorax trauma.[11] Therefore, the 
selective introduction of C3 Rho-inhibitor into PMNs would be 
highly desirable for such applications.
Herein, we developed PMN-selective Rho-inhibitors based 
on the supramolecular assembly of C3 Rho-inhibitor and spe-
cific PMN-targeting peptides on an avidin (Avi) platform to pro-
vide cell-type selectivity. The PMN-targeting peptide sequences 
have previously been identified using random peptide phage 
display that addresses the neutrophils specifically.[22–24] For 
instance, the Ac-GGPNLTGRWGPPVESALAK-NH2 (GGP) 
sequence reveals neutrophil and monocyte selective binding, 
which has been applied to liposomes for targeted delivery.[25] In 
addition, the peptide cinnamoyl-F(D)LF(D)LFK-NH2 (FK), an 
antagonist of the formyl peptide receptor 1 (FPR-1) of neutro-
phils, has been conjugated to imaging agents or nanoparticles 
for in vivo imaging.[26,27]
Although peptide sequences such as GGP could be recom-
binantly fused to C3 Rho-inhibitor, the expression of C3 enzyme 
with cyclic or chemically modified peptides, such as FK cannot 
be achieved by molecular biology techniques. Furthermore, 
the fusion of multiple peptide sequences to a single enzyme 
is challenging by genetic means and would require tedious 
optimization.[28,29] Release characteristics are controlled by 
chemical linker design to impart a variety of stimulus-respon-
sive groups for, e.g., pH-controlled release in acidic endosomal 
vesicles or inside the cytoplasm of cancer cells, which is also 
challenging to achieve by genetic engineering.[30] Hence, there 
is a great interest in novel “chemistry” methods to design and 
produce customized protein drugs.[31,32] In particular, supra-
molecular assembly of protein complexes provides convenient 
access to sophisticated multiprotein architectures that cannot 
be achieved by molecular biology methods.[31]
The assembly of multiprotein complexes that contained 
functional subunits of bacterial protein toxins and den-
drimers[33,34] or multiple copies of the cancer-cell targeting 
peptide somatostatin at an avidin platform has been estab-
lished by our groups before. Recently, we have reported the 
selective delivery of a supramolecular complex that contains 
the Rho-inhibitor C3bot1 (henceforth C3) and somatostatin 
as cell-targeting peptide into the cytosol of human cancer cells 
overexpressing the somatostatin receptor, resulting in reduced 
growth of a human xenograft lung tumor.[35] The best effect 
was achieved when three somatostatin peptides and one C3 
enzyme were bound to the avidin platform presumably via 
the multivalency effect.[35] We further expand on this versatile 
strategy and report herein for the first time the stoichiometric-
controlled assembly of 1) multiple copies of different PMN-tar-
geting peptides and 2) C3 Rho-inhibitor via 3) a pH-cleavable 
hydrazone linker for controlled intracellular release of the C3 
enzyme into the cytosol of PMNs (Figure 1). Our platform 
allows rapid generation of different supramolecular toxin com-
binations, e.g., by varying the PMN-targeting peptides, which 
is highly desirable for throughput synthesis and screening to 
evaluate the efficacy of the different combinations of the C3 
Rho-inhibitor and different PMN targeting peptide sequences. 
We believe that our approach offers great potential for the 
development of cell type-selective biotherapeutics for the tar-
geted treatment of local and systemic inflammation, e.g., after 
traumatic injury of multiple injured patients in a convenient 
“mix-and-match” assembly.
2. Results and Discussion
2.1. “Mix-and-Match” Assembly and Characterization of the 
Supramolecular Complexes (GGP)3-Avi-C3 and (FK)3-Avi-C3
The supramolecular complexes (GGP)3-Avi-C3 and (FK)3-Avi-C3 
containing the PMN-targeting peptides GGP and FK as well as 
C3 (Figure 1) were both designed based on avidin–biotin tech-
nology. Avidin (Avi), the central platform for assembly, is a tetra-
meric protein (pI > 9) that forms strong noncovalent interactions 
(Kd = 10−15 m) with its natural binding partner biotin at four 
binding sites. Here, Avi is selected as a monodisperse supramo-
lecular “glue” to combine the PMN-targeting peptides and C3 
Rho-inhibitor at spatially distinct locations. To incorporate biotin 
into the Ac-GGPNLTGRWGPPVESALAK-NH2 (GGP) sequence, 
GGP was functionalized using a bifunctional maleimide-biotin 
with a short ethylene glycol linker (compound 1, Figure 2A) that 
improves water solubility. The biotinylated GGP (B-GGP) peptide 
was obtained in 40% yield after high-performance liquid chro-
matography (HPLC) purification with >95% purity (Figure S4, 
Supporting Information). The PMN-targeting peptide cin-
namoyl-F(D)LF(D)LFK-NH2 (FK) with a biotin at the C-terminus 
(Figure 2B) was purchased commercially (PhtdPeptides Co., Ltd. 
with 95% purity). To control the stoichiometry of peptides with 
terminal biotin bound to Avi, a competitive binding assay with 
2-(4-hydroxyphenylazo)benzoic acid (HABA) was performed. 
HABA binds to Avi with lower affinity compared to biotin and 
shows absorbance at 500 nm in the complexed form (Figure 2C). 
Thus, disappearance of the absorption peak indicates displace-
ment of HABA by biotin. A stepwise reduction in absorbance 
was observed upon addition of 1–4 equivalents of biotin indi-
cating the controlled binding of the respective biotinylated neu-
trophil targeting peptide to Avi (Figure 2C).
It was determined that 1.25 mole equiv of B-GGP and 1.0 
mole equiv of B-FK are required per binding pocket in Avi, 
Adv. Healthcare Mater. 2019, 8, 1900665
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respectively, most likely for steric reasons. Subsequently, the 
transporters with three biotinylated peptides per Avi were 
prepared by mixing the corresponding mole equiv of B-GGP 
or B-FK with Avi (Figure 2D). These (GGP)3-Avi or (FK)3-Avi 
conjugates offer a free available binding site for conjugation to 
mono-biotinylated C3.
Next, mono-biotinylation of a cysteine mutant of C3 was 
accomplished. The enzyme activity and substrate specificity as 
well as the biological activity of this recombinant C3 variant has 
been confirmed earlier in J774A.1 macrophages and osteoclast-
like RAW 264.7 cells.[21] A biotin-maleimide conjugation with 
a pH-sensitive hydrazone linkage (4) that allows cleavage at 
acidic pH was synthesized with modification from a procedure 
published previously (Figure 3A and Scheme S1, Supporting 
information).[35] The pH-sensitive hydrazone triggers controlled 
toxin release in acidic endosomal compartments of the cells.[35] 
Compound 4 was conjugated to C3 to afford mono-biotinylated 
C3 (B-C3, Figure 3B) in 78% yield, determined by bicinchoninic 
acid (BCA) assay and Quant*Tag  biotin quantification assay 
(Figure S3, Supporting Information). The successful biotinyla-
tion was determined using Western blot analysis (Figure 5), 
and the degree of biotinylation was quantified to be 91% using 
the Quant*Tag Biotin Kit (Figure S3, Supporting Information).
The controlled assembly of (GGP)3-Avi-C3 and (FK)3-Avi-C3 
was accomplished through stoichiometric control according 
to the optimized ratio of 1.25 equiv of B-GGP and 1.0 equiv 
of B-FK per binding pocket (GGP-B:Avi:B-C3 = 3.75:1:1); 
(B-FK:Avi:B-C3 = 3:1:1, Figure 4A). Sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) analysis of 
(GGP)3-Avi-C3 and (FK)3-Avi-C3 with and without heating 
against a known concentration of B-C3bot1 (Figure 4B) further 
revealed that nearly all of the C3 protein reacted during the con-
jugation reaction, confirming the formation of the supramole-
cular complexes. The height profile of the constructs (3–6 nm) 
was determined by using atomic force microscopy (AFM) and 
no larger aggregates were detected indicating sample homoge-
neity (Figure 4C). Furthermore, no aggregates were detected 
by dynamic light scattering in solution (Table S1, Supporting 
Information). The zeta-potential of (FK)3-Avi-C3 and (GGP)3-
Avi-C3 was determined to be −4.56 and −2.39 mV, respectively, 
which is consistent with the theoretical isoelectric point (pI) of 
FK (pI = 6) and GGP (pI = 9) peptides (Table S2, Supporting 
Information).
Next, the stoichiometry of the complexes was assessed 
using absorption spectroscopy of dye-labeled constructs. First, 
(GGP)3-Avi-C3 was triply labeled with dyes in a controlled 
fashion: First, Avi was labeled with Alexa-594 dye, B-C3 was 
functionalized with Alexa-647 dye and GGP with Alexa-488 
(details are given in the Supporting Information). The ratio of 
GGP:Avi:C3 was determined from the absorption envelopes 
using a multiplate reader and a ratio of 3.2:1:0.7 was calculated 
(Figure 4B). Similarly, absorbance measurement of a dual-
labeled (FK)3-Avi-C3 construct was determined to give a ratio of 
Avi:C3 of 1:0.8 (Figure S7, Supplementary Information).
The assembly and pH-induced release was further demon-
strated with the construct, (FK)3-Avi-C3, through fluorescence 
resonance energy transfer (FRET) study (Figure 5A). The 
labeled proteins and peptides were prepared as outlined in 
Adv. Healthcare Mater. 2019, 8, 1900665
Figure 1. Design and potential mode of action of supramolecular complexes containing specific PMN-targeting peptides and C3-Rho-inhibitor assem-
bled on a central avidin (Avi) platform. The resultant protein complex is designed to selectively internalize into PMNs where the C3-catalyzed Rho-
inhibition down-modulates Rho-signaling in order to modulate PMN functions such as migration and chemotaxis.
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Figure 4A. Only when the donor–acceptor dye pairs are in close 
proximity (<10 nm), an energy transfer is observed in the fluo-
rescence spectrum,[36] which confirms the assembly. Upon exci-
tation at 550 nm in the absorption maximum of Alexa-594 dye 
(purple star), an emission band was observed at 680 nm, indi-
cating energy transfer from the Avi to B-C3 (Figure 5A, left). No 
energy transfer was observed for the negative controls (FK)3-Avi 
alone or (FK)3-Avi mixed with nonbiotinylated C3 (Figure 5A, 
left), thereby corroborating the successful assembly. Upon incu-
bation of the construct at pH 4.5 for 4 h, the FRET is no longer 
observed (Figure 5A, right), confirming the pH-induced release 
of C3 in acidic environment. To ensure that the construct can be 
successfully applied in biological media, the stability of (FK)3-
Avi-C3 was investigated in fetal calf serum (FCS). (FK)3-Avi-C3 
was incubated for up to 24 h in 10% FCS in phosphate buffer 
saline (PBS) and Western blot analysis was applied to monitor 
its stability. Notably, no increase in free C3 was observed up to 
24 h (Figure 5B), which would have indicated disintegration of 
the construct. To eliminate false positive due to absorption of 
C3 by serum proteins, FRET measurements were performed, 
indicating the presence of molecular and nondegraded (FK)3-
Avi-C3 in 10% FCS (Figure S10, Supporting Information). 
Taken together, our results show the successful assembly of 
the (FK)3-Avi-C3 and (GGP)3-Avi-C3 constructs with about one 
C3 per conjugate, thus supporting the postulated formulation. 
Furthermore, the release of C3 was induced under acidic condi-
tions in vitro and the constructs remained stable in biological 
media such as FCS.
2.2. The Supramolecular Complexes (GGP)3-Avi-C3 and (FK)3-
Avi-C3 are Selectively Internalized into Neutrophil-Like NB-4 
Cells and C3 is Released into Their Cytosol
The selective delivery of the Rho-inhibitor C3 into the cytosol 
of neutrophils by either (GGP)3-Avi or (FK)3-Avi was investi-
gated as proof-of-concept for these novel transporter molecules. 
First, human NB-4 cells, a neutrophil-like cell line, were used 
to test the ability of (GGP)3-Avi and (FK)3-Avi to deliver the C3 
Rho-inhibitor into the cytosol of these cells. Therefore, differ-
entiated NB-4 cells were incubated at 37 °C with either (GGP)3-
Avi-C3 or (FK)3-Avi-C3. For negative controls, the Avi alone and 
the C3 protein alone were applied. Moreover, cells remained 
untreated as a further control. The recombinant fusion toxin 
C2IN-C3lim is a specific Rho inhibitor based on the C3lim 
enzyme. In combination with the C2IIa transport component 
of the binary C2 toxin from C. botulinum served as positive con-
trol.[37] C2IN-C3lim alone is specifically taken up into mono-
cytic cells, but essentially requires C2IIa for its uptake into the 
cytosol of other cell types such as epithelial cells. Therefore, in 
Adv. Healthcare Mater. 2019, 8, 1900665
Figure 2. A) Synthesis of biotinylated GGP (B-GGP, H2O:DMF, 1:0.5, 7.5 mL), room temperature, overnight, 40% isolated yield. B) Chemical structure 
of B-FK peptide. C) Competitive binding of 2-(4-hydroxyphenylazo)benzoic acid (HABA) and biotin to avidin (Avi). The amount of B-GGP or B-FK 
required to saturate a tetrameric Avi was determined using the HABA assay. In the case of B-FK 4 mole equiv saturated the binding sites of Avi, while 
5 mole equiv of B-GGP are required to saturate the binding sites of Avi. D) Assembly of neutrophil targeting transporters (GGP)3-Avi and (FK)3-Avi.
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combination with C2IIa, the uptake of C2IN-C3lim is not cell-
type selective.[10,37]
In the next step, we determined the characteristic C3-induced 
changes in cell morphology (Figure 6A) after release of C3 into 
the cytosol of NB-4 cells. Images of the cells were recorded 
after different incubation periods and the number of these 
intoxicated cells was determined based on the morphological 
changes (Figure 6B). This is a well-established,[15,17,18,21,35,37,38] 
highly sensitive and specific endpoint to monitor the uptake 
of C3 Rho-inhibitor into the host cell cytosol. The changes in 
cell morphology essentially depend on the C3-catalyzed ADP-
ribosylation of Rho in the cytosol.[15,17,18,21,35,37] As expected, the 
combination of C2IN-C3lim and C2IIa exhibited the strongest 
effect while C3 alone and the platform (Avi) alone had almost 
no effect on cell morphology. Importantly, treatment of NB-4 
with (GGP)3-Avi-C3 as well as (FK)3-Avi-C3 resulted in a sig-
nificantly increased number of cells showing the characteristic 
C3-induced morphology when compared to untreated control 
cells (Figure 6A,B). This indicates that C3 enzyme activity 
reached the cytosol of NB-4 cells after their treatment with 
either (GGP)3-Avi-C3 or (FK)3-Avi-C3 ex vivo.
The ability of both transporters to deliver the Rho-inhibitor 
C3 into the cytosol of NB-4 cells was also confirmed by the bio-
chemical analysis of the ADP-ribosylation status of Rho from 
these cells and exemplarily shown for (FK)3-Avi-C3 (Figure 6C). 
In this assay, the ADP-ribosylation status of Rho was analyzed 
in cell lysates by sequential ADP-ribosylation with biotin-labeled 
NAD+.[37,38] A strong signal in the Western blot indicated that 
no Rho ADP-ribosylation took place in the intact cells. In con-
trast, a weak signal in the blot indicated that all/most of the 
Rho protein have already undergone ADP ribosylation in the 
intact cells during the incubation with the C3-containing com-
pounds or fusion toxins and therefore is proofed unsuitable as 
a substrate for the subsequent in vitro ADP-ribosylation with 
biotin NAD+. The observation that C3 alone had no comparable 
effect as (GGP)3-Avi-C3 or (FK)3-Avi-C3 regarding the mor-
phology change and the ADP-ribosylation of Rho in the cells 
indicated that (GGP)3-Avi or (FK)3-Avi are essential for the 
transport of C3 into the cytosol of the neutrophils. Moreover, it 
excluded the possibility that C3 was separated from the trans-
porters (GGP)3-Avi or (FK)3-Avi already in the medium during 
the incubation with the cells and that some resulting free C3 
might have caused the observed effects in the neutrophils inde-
pendently from the supramolecular transporters.
2.3. Effect of (GGP)3-Avi-C3 and (FK)3-Avi-C3 on Primary PMNs 
Isolated from the Human Blood
After successful demonstration of the transport of the Rho 
inhibitor C3 into the cytosol of a human neutrophil-like cell 
line by both supramolecular C3-containing complexes, the 
effect of (GGP)3-Avi-C3 and (FK)3-Avi-C3 on biologically and 
medically more relevant primary human PMNs was investi-
gated. PMNs were isolated from the blood of healthy human 
volunteers and incubated at 37 °C with either (GGP)3-Avi-C3 or 
Adv. Healthcare Mater. 2019, 8, 1900665
Figure 3. A) Synthesis of compound 4 B) Mono-biotinylation of C3 C) Matrix-assisted laser desorption/ionization (MALDI)-time of flight (ToF) mass 
spectrometry (MS) spectra of C3 (green) m/z = 24 484 and biotinylated C3 (B-C3) m/z = 24 735 using CHCA as matrix. D) Acidic cleavage of B-C3.
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(FK)3-Avi-C3. Images of the cells were taken and the changes 
in cell morphology were compared with cells left untreated or 
treated with either Avi alone or C3 alone. The fusion toxin, 
C2IN-C3lim+ C2IIa, where C2IIa delivers the Rho-inhibitor 
C2IN-C3lim into the cytosol of all cell types, served as posi-
tive control. Like the NB-4 cells, the human PMNs responded 
with significant changes in cell morphology to the treatment 
with either (GGP)3-Avi-C3 or (FK)3-Avi-C3 and C2IN-C3lim + 
C2IIa (Figure 7A–C). However, neither Avi nor C3 had a com-
parable effect (Figure 7A,C). These results clearly indicated that 
(GGP)3-Avi-C3 and (FK)3-Avi-C3 were able to deliver C3 into the 
cytosol of primary human PMNs. Moreover, (GGP)3-Avi as well 
as (FK)3-Avi, but not Avi alone, bound to the surface of PMNs 
at 4 °C as analyzed by flow cytometry, confirming the specific 
function of the PMN targeting peptides (Figure 7D).
In contrast, neither (GGP)3-Avi-C3 nor (FK)3-Avi-C3 showed 
similar effects on the morphology of human lung epithelial 
cells A549 (Figure 8A and Figure S11A, Supporting Informa-
tion) or the recently established human alveolar epithelial cell 
line hAELVi (Figure 8C and Figure S11B, Supporting Infor-
mation), a model for the air–blood barrier of the peripheral 
lung,[39] implicating that in these cells, the Rho-inhibitor C3 
was not delivered into the cytosol by the supramolecular com-
plexes. These findings were confirmed by the biochemical 
evaluation of the ADP-ribosylation status of Rho of these cells 
(Figure 8B,D). Our results clearly indicate that C3 enzyme 
activity was not present in the cytosol of these epithelial cells. 
On the other hand, treatment of the A549 cells with C2IN-
C3lim + C2IIa resulted in the expected C3-induced change 
in cell morphology (Figure 8A and Figure S11A, Supporting 
Information) and the strong ADP-ribosylation of Rho in the 
cytosol of the living cells by C3 (Figure 8B,D).
3. Conclusion
In conclusion, PMN-targeting supramolecular multiprotein 
complexes consisting of the specific Rho-inhibitor C3, Avi as 
molecular glue and three PMN-targeting peptides were prepared 
by convenient “mix-and-match” assembly using Avi/biotin tech-
nology to inhibit Rho-mediated signal transduction in PMNs. 
(GGP)3-Avi-C3 or (FK)3-Avi-C3 were generated, characterized 
and their biological mode of action was evaluated in vitro and 
ex vivo. A set of cell-based experiments clearly underlined the 
efficient and cell type-selective transport of the Rho-inhibitor C3 
into the cytosol of primary human PMNs ex vivo and into the 
cytosol of human neutrophil-like NB-4 cells but not into human 
lung epithelial cells, which provides strong evidence for cell 
type-selectivity of (GGP)3-Avi and (FK)3-Avi. We envision that 
our strategy provides new therapeutic avenue for diseases such 
as post-traumatic injury of multiple injured patients, which are 
associated with hyperactivity and reactivity of PMNs.
Based on these seminal proof-of-concept investigations, 
future studies will focus on the application of the novel supra-
molecular complexes containing C3 Rho-inhibitor to eluci-
date whether inhibition of Rho-mediated signal transduction 
interferes with migration and chemotaxis of human PMNs 
in trans-well and human “lung-on-a-chip” approaches ex vivo. 
Adv. Healthcare Mater. 2019, 8, 1900665
Figure 4. Assembly of the supramolecular complexes (FK)3-Avi-C3 and (GGP)3-Avi-C3 and their characterization. A) The controlled assembly of (GGP)3-
Avi-C3 and (FK)3-Avi-C3 was accomplished through stoichiometric control according to the optimized ratio of 1.25 equiv of B-GGP and 1.0 equiv of B-FK 
per binding pocket. B) SDS-PAGE characterization of the protein complexes under denaturing and nondenaturing conditions indicate the successful 
assembly by the disappearance of C3 band under nondenaturing conditions. C) AFM image of (FK)3-Avi-C3 with height profile analysis of protein 
particles. D) Absorbance spectrum of (GGP)3-Avi-C3. Avi was labeled with Alexa-594 dye (purple star), B-C3 was labeled with Alexa-647 dye (blue star) 
and GGP with Alexa-488 (orange star). The ratio of GGP:Avi:C3 was determined from the absorption envelopes and a ratio of 3.2:1:0.7 was calculated.
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Moreover, it will be tested by our established animal model 
whether the local intratracheal application of the novel supra-
molecular C3-containing complexes decreases the enhanced 
invasion of PMNs from the blood into the lungs of mice after 
blunt thorax trauma. This approach is inspired by earlier proof-
of-concept studies which indicate that the intratracheal appli-
cation of the recombinant Rho-inhibiting C3IN-C3lim fusion 
toxin significantly reduced the amount of monocytic cells in 
the lungs of mice after blunt thorax trauma, but had no effect 
on PMNs because of its cell type-selectivity.[11] Besides, the sta-
bility of the complexes in vivo, e.g., in human blood will also 
be investigated. Ultimately, we envision the application of 
supramolecular toxin complexes to downmodulate excessive 
PMN recruitment and migration across the disturbed alveolar 
barrier of patients after trauma—a hallmark event in the pro-
gression of Acute Lung Injury and Acute Respiratory Distress 
Syndrome.[40,41]
4. Experimental Section
General information, methods for AFM, dynamic light scattering 
(DLS), Zeta-potential, SDS-PAGE and Western blot analysis are 
provided in the Supporting Information.
Materials: Unless otherwise stated, all chemicals were obtained from 
commercial sources (Merck, Sigma Aldrich, Fluka and Thermo Scientific, 
Fisher Scientific) and used without further purification. All organic 
solvents (acetonitrile (CH3CN), chloroform (CHCl3), dichlormethane 
(DCM), dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 
methanol (MeOH)) were obtained from Fisher Scientific and used 
without further purification (HPLC or analytical grades). The peptides 
Ac-GGPNLTGRWGPPVESALAK-NH2 (GGP) and cFLFLFK-Biotin (B-FK) 
were purchased from PhtdPeptides Co., Ltd. (Zhengzhou City, China) 
with 95% purity. Water used for the reactions was obtained from the 
Merck Millipore purification system.
Cell culture media (Dulbecco’s modified Eagle’s medium (DMEM), 
Roswell Park Memorial Institute (RPMI) 1640 Medium) and fetal calf 
serum were from Gibco Life Technologies (Karlsruhe, Germany), cell 
culture materials from TPP (Trasadingen, Switzerland) and Sarstedt 
(Nümbrecht, Germany). Monovettes were from Sarstedt (Nümbrecht, 
Germany) and Biocoll Separating Solution from Biochrom GmbH 
(Berlin, Germany). Penicillin–streptomycin and Page Ruler prestained 
protein ladder were purchased from Thermo Fisher Scientific (Ulm, 
Germany). Page Ruler unstained protein ladder was purchased from 
GE Healthcare Life Sciences (Uppsala, Sweden). Complete protease 
inhibitor and streptavidin–peroxidase were from Roche (Mannheim, 
Germany) and biotinylated NAD+ from R&D Systems GmbH 
(Wiesbaden-Nordenstadt, Germany). The antibody against GAPDH and 
the peroxidase-coupled antimouse binding protein were from Santa Cruz 
Biotechnology (Heidelberg, Germany). Thrombin was purchased from 
Sigma-Aldrich Chemie GmbH (Steinheim, Germany), the nitrocellulose 
blotting membrane from GE Healthcare Life Sciences (Uppsala, 
Sweden), and the enhanced chemiluminescence (ECL) system from 
Millipore (Schwalbach, Germany). All-trans-retinoic acid (ATRA) and 
N,N′-hexamethylene bis(acetamide) (HMBA) were from Sigma-Aldrich 
(Steinheim, Germany). G-CSF was purchased from Sino Biological 
Inc. (Wayne, PA, USA). The expression, purification and biochemical 
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Figure 5. A) Left: Emission spectrum of dual-labeled assembled construct (FK)3-Avi-C3 (blue), showing FRET and Avi (purple), (FK)3-Avi + C3, mixed 
(orange) as control. right: pH induced release, showing no FRET after 4 h incubation time at pH 4.5. B) Stability of (FK)3-Avi-C3 protein complex in fetal calf 
serum (FCS). Western blot analysis showed no significant increase up to 24 h. B-C3 and (FK)3-Avi-C3 in PBS as well as 10% FCS were applied as control.
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characterization of the recombinant proteins C2IIa, C2IN-C3lim, and 
cysteine mutant of C3 was performed as described earlier.[16,20,21]
Synthesis of (E)-N-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-
5-(2-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)
pentanoyl)hydrazineylidene)hexanamide 4: N-(2-(2.5-dioxo-2.5-dihydro-1H- 
pyrrol-1-yl)ethyl)-5-oxohexamide (63 mg, 0.25 mmol, 1 equiv) and 
5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol4-yl)penta-
nehydrazide (78 mg, 0.3 mmol, 1.2 equiv) were dissolved in 10 mL 
anhydrous MeOH under argon atmosphere. The resulting reaction 
mixture was heated to 50 °C and was continuously stirred for 4 h. The 
solvent was removed under high vacuum, and the residue was purified 
by column chromatography using eluting solvents 10% MeOH in 
DCM to afford 63 mg (0.12 mmol, 53%) of the final product; 1H-NMR 
(300 MHz, MeOD δ) 6.83 (s, 2H) 4.51 (m, 1H) 4.33 (m, 1H), 3.63 (m, 
2H), 3.36 (m, 2H), 3.22 (m, 1H) 2.94 (d, 1H, J = 12.7 Hz), 2.71 (d, 1H, 
J = 12.7 Hz), 2.11–2.44 (m, 6H), 1.98 (1H), 3.36 (m, 2H), 3.63 (m, 2H), 
4.33 (m, 1H), 4.51 (m, 1H), 6.83 (s, 2H). 13C-NMR (100 MHz, MeOD, 
δ) 176.20, 172.56, 165.93, 162.15, 135.45, 127.34, 63.41, 61.63, 56.96, 
Adv. Healthcare Mater. 2019, 8, 1900665
Figure 6. Effect of (GGP)3-Avi-C3 and (FK)3-Avi-C3 on human neutrophil-like NB-4 cells. A) Differentiated NB-4 cells were incubated with 320 × 10−9 m  
Avi, 320 nm (GGP)3-Avi-C3, 320 × 10−9 m (FK)3-Avi-C3, 1 µg mL−1 C2IN-C3lim + 2 µg mL−1 C2IIa, 320 × 10−9 m C3bot1 or left untreated for control (mock). 
The cells were incubated at 37 °C and cell morphology was observed by phase contrast microscopy and documented over 6 h. The arrows indicate 
cells showing characteristic changes in cell morphology induced by the C3 Rho-inhibitor. The scale bar represents 50 µm. B) Quantitative analysis 
of NB-4 cells showing the C3-induced morphology from pictures after 4 and 6 h. Values are given as mean ± SEM (n = 6). Significance was tested 
using Student’s t-test (ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001). C) Analysis of the ADP-ribosylation status of these cells. The cells were 
treated as described in (A) and subsequently lysed. Equal amount of lysate protein of each sample was subjected to in vitro ADP-ribosylation with C3 
enzyme and biotin-NAD+. The biotinylated, i.e., ADP-ribosylation of Rho was detected by Western blotting (upper panel). Note: A strong signal in the 
blot indicates that no ADP-ribosylation of Rho took place in the living cells, demonstrating that the C3 Rho-inhibitor was not present in their cytosol. 
A weak signal indicates that most ADP-ribosylation of the Rho protein took already place in the cytosol of the living cells by C3 Rho-inhibitor during 
the incubation period, indicating that active C3 enzyme reached the cytosol of these cells. Lower panel: GAPDH-staining to demonstrate comparable 
protein loading and blotting. 1) mock, 2) Avi, 3) (FK)3-Avi-C3, 4) C2IN-C3lim + C2IIa, 5) C3.
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Figure 7. Effect of (GGP)3-Avi-C3 and (FK)3-Avi-C3 on primary human PMNs ex vivo. A) PMNs were isolated from blood of healthy donors and then 
treated ex vivo with 320 × 10−9 m Avi, 320 × 10−9 m (GGP)3-Avi-C3, 320 × 10−9 m (FK)3-Avi-C3, 1 µg mL−1 C2IN-C3lim + 2 µg mL−1 C2IIa, 320 × 10−9 m C3 
or left untreated for control (mock). Cells were incubated at 37 °C and cell morphology was observed over a period of 6 h. Arrows indicate cells showing 
the characteristic changes in cell morphology induced by C3 Rho-inhibitor. The scale bar represents 50 µm. B) Cells of the same experiment with typical 
C3-induced morphology were enlarged for better visualization. C) Quantitative analysis of cells showing the C3-induced morphology from pictures 
after 4 and 6 h. Values are given as mean ± SEM (n = 9). Significance was tested using Student’s t-test (ns, not significant, *p < 0.05, ***p < 0.001). 
D) Analysis of the binding of (GGP)3-Avi-C3 and (FK)3-Avi-C3 to PMNs by flow cytometry. PMNs (200 000 cells in 200 µL complete medium) were 
incubated for 10 min at 4 °C with either Avi, (GGP)3-Avi-C3, or (FK)3-Avi-C3 (all labeled with bodipy-fl (BDP)) or left untreated for control (mock). 
Subsequently, the cells were washed and analyzed by flow cytometry for the cell-bound BDP-proteins. The median fluorescence (FL) intensity of the 
respective histogram peaks was calculated, normalized to untreated control (mock) and is shown as arbitrary units (AU). Values are given as mean ± 
SEM (n = 5). Significance was tested using Student’s t-test (ns, not significant, ***p < 0.001).
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41.03, 38.89, 38.41, 38.26, 35.68, 34.59, 29.80, 29.53, 26.62, 23.53, 16.54. 
Liquid chromatography–mass spectrometry (LC–MS): TR: 3.51 min, m/z: 
493 [M+H]+, 515 [M+Na]+, 253 [2+Na]+ (calcd. mass: 492.22, formula: 
C22H32N6O5S).
Biotinylation of Ac-GGPNLTGRWGPPVESALAK-NH2 (B-GGP): A 
2 mg mL−1 solution of GGP-peptide (5 mg, 2.5 µmol) in DMF and a 
1 mg mL−1 solution of biotin-(PEO)3-maleimide in phosphate buffer 
(50 × 10−3 m, pH 7.4) were mixed and incubated overnight at RT under 
shaking. The respective solution was lyophilized and washed with DCM 
to remove unreacted biotin reagent. The crude product was further 
purified by HPLC using a XDB-C18 column with the mobile phase 
starting from 100% solvent A (0.1% TFA in water) and 0% solvent B 
(0.1% TFA in acetonitrile) (0–5 min) with a flow rate of 4 mL min−1, 
raising to 5% solvent B in 5 min, 15% solvent B in 10 min, and then 
reaching 100% solvent B after 29 min. It remained in this state for 
1 min. Solvent B concentration was then finally lowered to 5% over five 
minutes. Absorbance was monitored at 280 and 254 nm. The retention 
time for GGP-B was 17.5 min, and 2.75 mg (1.02 µmol, 40%) of the 
product was obtained after lyophilization; LC–MS: TR: 4.51, m/z: 898 
[M+3H]3+. MALDI-ToF-MS (CHCA): m/z: 2691 [M+H]+, 2713 [M+Na]+, 
(calcd. mass: 2689 formula: C120H192N32O34S2).
Biotinylation of C3 (B-C3): The recombinant cysteine mutant of C3 
was expressed and purified in Escherichia coli BL21 as described in the 
literature.[35]
60 µL of 4-(2-hydroxyethyl)-1-piperazine–ethanesulfonic acid 
(HEPES) buffer (100 × 10−3 m, pH 7.4) and tris(2-carboxyethyl)phosphine 
(TCEP) HCl were sequentially added to the C3 solution (200 µg, 
8 nmol, 1 equiv) and were incubated for 30 min at RT under shaking 
. Subsequently, 30 µL of compound 3 (5 mg mL−1 in DMF, 30 equiv) 
were added to the reaction mixture and the resulting mixture was 
shaken for 3 h at 4 °C. Thereafter, rigorous ultrafiltration with 3 × 500 µL 
buffer (molecular weight cut off (MWCO) = 10 kDa, 25 × 10−3 m  
HEPES buffer, pH 7.4) was used to remove excess of compound 3 to 
yield 208 µL B-C3 (0.7 mg mL−1, 73% yield). The concentration of B-C3 
was determined using a bicinchoninic acid (BCA) assay (A562 nm) with 
BSA as reference. Successful biotinylation was confirmed by MALDI-
ToF-MS (Figure 3C) and degree of labeling was quantified by Quant*Tag 
Biotin Kit at A535 nm.
Assembly of Transport Proteins (GGP)3-Avi and (FK)3-Avi: (GGP)3-Avi 
was assembled by dissolving 2 mg (31.7 nmol, 1 equiv) of Avi-BDP in 
1 mL phosphate buffer (50 × 10−3 m, pH 7.4) and subsequent adding 
383 µL GGP-B (383 µg in MilliQ water, 143 nmol, 4.5 equiv). The mixture 
was incubated for 1 h at RT under shaking and purified by rigorous 
ultracentrifugation (MWCO = 20 kDa, using 3 × 500 µL 50 × 10−3 m 
phosphate buffer pH 7.4). (FK)3-Avi was assembled by dissolving 1 mg 
(15.9 nmol, 1 equiv) Avi-BDP in 1 mL phosphate buffer (50 × 10−3 m, 
pH 7.4) and 5.57 µL FK-B (56 µg in DMSO, 47.7 nmol, 3 equiv) were 
subsequently added. The mixture was incubated for 1 h at RT under 
shaking and purified by ultracentrifugation (MWCO = 20 kDa, using 
3 × 800 µL 50 × 10−3 m phosphate buffer pH 7.4).
Assembly of (GGP)3-Avi-C3 and (FK)3-Avi-C3: (FK)3-Avi-C3 was 
assembled by using 66 µL Avi-BDP (2 mg mL−1 in HEPES buffer 
25 × 10−3 m, pH 7.4) dissolved in 100 µL of HEPES buffer (50 × 10−3 m, 
pH 7.4). Then, 62 µL (0.8 mg mL−3 in 25 × 10−3 m HEPES buffer pH 7.4, 
Figure 8. Effect of (GGP)3-Avi-C3 and (FK)3-Avi-C3 on human A549 lung cancer epithelial cells and on the human alveolar epithelial cell line hAELVi. 
A) A549 cells were treated with 320 ×10−9 m Avi, 320 ×10−9 m (GGP)3-Avi-C3, 320 ×10−9 m (FK)3-Avi-C3, 1 µg mL−1 C2IN-C3lim + 2 µg mL−1 C2IIa, 
320 ×10−9 m C3 or left untreated for control (mock). Cells were incubated at 37 °C and cell morphology was analysis after a period of 4 and 6 h. Values 
are given as mean ± SD (n = 3). Significance was tested using Student’s t-test (ns, not significant, ***p < 0.001). B) Analysis of the ADP-ribosylation 
status of these cells. The cells were treated as described in (A) and then lysed. Equal amount of lysate protein of each sample was subjected to in vitro 
ADP-ribosylation with C3 enzyme and biotin-NAD+. The biotinylated, i.e., ADP-ribosylation of Rho was detected by Western blotting (upper panel). A 
strong signal in the blot indicates that no ADP ribosylation of Rho took place in the living cells, demonstrating that no C3 Rho-inhibitor was present 
in their cytosol. A weak signal indicates that most ADP-ribosylation of the Rho took already place in the cytosol, of the living cells during the incuba-
tion period. Lower panel: GAPDH-staining to demonstrate comparable protein loading and blotting. 1) mock, 2) Avi, 3) (FK)3-Avi-C3, 4) C2IN-C3lim + 
C2IIa, 5) C3, 6) (GGP)3-Avi-C3. C) hAELVi cells were treated with 320 × 10−9 m Avi, 320 ×10−9 m (GGP)3-Avi-C3, 320 × 10−9 m (FK)3-Avi-C3, 3 µg mL−1 
C2IN-C3lim + 6 µg mL−1 C2IIa, 320 × 10−9 m C3 or left untreated for control (mock). Cells were incubated at 37 °C and cell morphology was analyzed after 
a period of 4 and 6 h. Values are given as mean ± SEM (n = 9). Significance was tested using Student’s t-test (ns, not significant, *p < 0.05, **p < 0.01, 
***p < 0.001). D) Analysis of the ADP-ribosylation status of these cells. The cells were treated as described in (C) and then lysed. Equal amount of 
lysate protein of each sample was subjected to in vitro ADP-ribosylation with C3 enzyme and biotin-NAD+. The biotinylated, i.e., ADP-ribosylation of 
Rho was detected as described in (B) 1) mock, 2) Avi, 3) (FK)3-Avi-C3, 4) C2IN-C3lim + C2IIa, 5) C3.
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50 µg, 2.0 nmol, 1 equiv) of B-C3 and 0.7 µL of B-FK (1 mg mL−1 in 
DMSO, 6.0 nmol, 3 equiv) were added.
(GGP) 3-Avi-C3 was assembled by using 66 µL (2 mg mL−1 in 
HEPES buffer 25 × 10−3 m, pH 7.4) of Avi-BDP dissolved in 100 µL of 
HEPES buffer (50 × 10−3 m, pH 7.4) and adding 62 µL (0.8 mg mL−1 in 
25 × 10−3 m HEPES buffer pH 7.4, 50 µg, 2.0 nmol, 1 equiv) of B-C3 and 
24 µL of B-GGP (1 mg mL−1 in MilliQ water, 9.0 nmol, 4.5 equiv).
Analysis of the ADP-Ribosylation Status of Rho in Cells: To analyze the 
ADP-ribosylation of Rho in the cytosol of cells, in vitro ADP-ribosylation 
with biotin-labeled NAD+ as cosubstrate and C3 enzyme was performed 
as described earlier.[11,17,37] In brief, cells were incubated at 37 °C with the 
respective transporters and toxins or left untreated for control as described 
in the previous section. Then, the cells were lysed and equal amount of 
lysate protein was incubated with 10 × 10−3 m biotin-labeled NAD+ and 
300 ng C3 for 30 min at 37 °C. The enzyme reaction was terminated by 
adding SDS sample buffer and boiling the samples at 95 °C for 10 min. 
The biotinylated, i.e., ADP-ribosylation of Rho was detected by Western 
blotting with streptavidin-peroxidase using the ECL system. To confirm 
comparable amount of blotted protein, GAPDH was detected in addition.
Flow Cytometry: PMNs were isolated as described before. For 
flow cytometry analysis 2 × 105 cells in 100 µL RPMI + 1% FCS were 
incubated with Avi (320 × 10−9 m), (GGP)3-Avi-C3 (320 × 10−9 m), or 
(FK)3-Avi-C3 (320 × 10−9 m) for 10 min on ice to prevent an endocytic 
uptake. Cells were washed with ice-cold PBS, resuspended in 200 µL 
complete medium and analyzed by flow cytometry using BD FACSCelesta 
flow cytometer and the BD FACSDiva software. BDP was excited 
with a blue laser (488 nm), emitted fluorescence was detected with a 
530 nm (530/30) bandpass filter. Analysis and creation of fluorescence 
histograms from gated cell populations was performed using Flowing 
Software v2.5.1 (Perttu Terho, Turku Centre for Biotechnology, Finland).
Statistical Analysis: Preprocessing of data was performed as described 
in each experimental section. The results were presented as mean ± SD 
or mean ± SEM as described in each figure description. Sample sizes 
are given in figure legends or as described in this section. Analyses 
comparing means of different treatment groups were performed using 
Student’s test (GraphPad Prism 5; GraphPad Software, Inc.) and p 
values less than 0.05 were considered significant.
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